Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.58
JAZZ's Cash to Debt is ranked lower than
84% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. JAZZ: 0.58 )
Ranked among companies with meaningful Cash to Debt only.
JAZZ' s 10-Year Cash to Debt Range
Min: 0.1  Med: 0.90 Max: No Debt
Current: 0.58
Equity to Asset 0.40
JAZZ's Equity to Asset is ranked lower than
77% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. JAZZ: 0.40 )
Ranked among companies with meaningful Equity to Asset only.
JAZZ' s 10-Year Equity to Asset Range
Min: -0.84  Med: 0.39 Max: 0.87
Current: 0.4
-0.84
0.87
F-Score: 7
Z-Score: 4.58
M-Score: -2.67
WACC vs ROIC
5.15%
12.19%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 30.68
JAZZ's Operating margin (%) is ranked higher than
92% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. JAZZ: 30.68 )
Ranked among companies with meaningful Operating margin (%) only.
JAZZ' s 10-Year Operating margin (%) Range
Min: -365.84  Med: 14.54 Max: 46.95
Current: 30.68
-365.84
46.95
Net-margin (%) 17.95
JAZZ's Net-margin (%) is ranked higher than
86% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. JAZZ: 17.95 )
Ranked among companies with meaningful Net-margin (%) only.
JAZZ' s 10-Year Net-margin (%) Range
Min: -397.15  Med: -0.17 Max: 49.25
Current: 17.95
-397.15
49.25
ROE (%) 16.94
JAZZ's ROE (%) is ranked higher than
90% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. JAZZ: 16.94 )
Ranked among companies with meaningful ROE (%) only.
JAZZ' s 10-Year ROE (%) Range
Min: 4.38  Med: 30.91 Max: 111.92
Current: 16.94
4.38
111.92
ROA (%) 6.81
JAZZ's ROA (%) is ranked higher than
85% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. JAZZ: 6.81 )
Ranked among companies with meaningful ROA (%) only.
JAZZ' s 10-Year ROA (%) Range
Min: -113.42  Med: -2.00 Max: 64.21
Current: 6.81
-113.42
64.21
ROC (Joel Greenblatt) (%) 277.87
JAZZ's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. JAZZ: 277.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
JAZZ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8082.84  Med: 524.16 Max: 11266.93
Current: 277.87
-8082.84
11266.93
Revenue Growth (3Y)(%) 47.60
JAZZ's Revenue Growth (3Y)(%) is ranked higher than
90% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. JAZZ: 47.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
JAZZ' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 24.30 Max: 47.6
Current: 47.6
0
47.6
EBITDA Growth (3Y)(%) 22.40
JAZZ's EBITDA Growth (3Y)(%) is ranked higher than
78% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. JAZZ: 22.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
JAZZ' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 22.40 Max: 75.9
Current: 22.4
0
75.9
EPS Growth (3Y)(%) -29.60
JAZZ's EPS Growth (3Y)(%) is ranked lower than
78% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. JAZZ: -29.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
JAZZ' s 10-Year EPS Growth (3Y)(%) Range
Min: -66.4  Med: 4.40 Max: 76.1
Current: -29.6
-66.4
76.1
» JAZZ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

JAZZ Guru Trades in Q3 2014

Paul Tudor Jones 1,600 sh (+14.29%)
Pioneer Investments 311,004 sh (unchged)
Jim Simons Sold Out
RS Investment Management 289,982 sh (-10.25%)
Steve Mandel 1,788,607 sh (-14.30%)
NWQ Managers 138,705 sh (-32.97%)
» More
Q4 2014

JAZZ Guru Trades in Q4 2014

Steve Mandel 1,883,654 sh (+5.31%)
RS Investment Management 287,828 sh (-0.74%)
Paul Tudor Jones 1,400 sh (-12.50%)
Pioneer Investments 253,843 sh (-18.38%)
NWQ Managers 64,783 sh (-53.29%)
» More
Q1 2015

JAZZ Guru Trades in Q1 2015

Ken Fisher 1,300 sh (New)
Joel Greenblatt 10,874 sh (New)
Pioneer Investments 322,932 sh (+27.22%)
NWQ Managers 64,824 sh (+0.06%)
Paul Tudor Jones Sold Out
RS Investment Management 250,474 sh (-12.98%)
Steve Mandel 260,985 sh (-86.14%)
» More
Q2 2015

JAZZ Guru Trades in Q2 2015

Ken Fisher 1,300 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with JAZZ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 54.80
JAZZ's P/E(ttm) is ranked lower than
57% of the 215 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. JAZZ: 54.80 )
Ranked among companies with meaningful P/E(ttm) only.
JAZZ' s 10-Year P/E(ttm) Range
Min: 10.72  Med: 24.60 Max: 415.7
Current: 54.8
10.72
415.7
Forward P/E 15.48
JAZZ's Forward P/E is ranked higher than
77% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 24.04 vs. JAZZ: 15.48 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 54.90
JAZZ's PE(NRI) is ranked lower than
58% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 39.20 vs. JAZZ: 54.90 )
Ranked among companies with meaningful PE(NRI) only.
JAZZ' s 10-Year PE(NRI) Range
Min: 11.86  Med: 24.16 Max: 411.84
Current: 54.9
11.86
411.84
P/B 8.62
JAZZ's P/B is ranked lower than
71% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. JAZZ: 8.62 )
Ranked among companies with meaningful P/B only.
JAZZ' s 10-Year P/B Range
Min: 2.46  Med: 6.63 Max: 32.21
Current: 8.62
2.46
32.21
P/S 9.70
JAZZ's P/S is ranked higher than
55% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. JAZZ: 9.70 )
Ranked among companies with meaningful P/S only.
JAZZ' s 10-Year P/S Range
Min: 0.22  Med: 5.47 Max: 12.01
Current: 9.7
0.22
12.01
PFCF 39.49
JAZZ's PFCF is ranked higher than
54% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 45.01 vs. JAZZ: 39.49 )
Ranked among companies with meaningful PFCF only.
JAZZ' s 10-Year PFCF Range
Min: 11.82  Med: 17.85 Max: 91.28
Current: 39.49
11.82
91.28
POCF 27.77
JAZZ's POCF is ranked higher than
61% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. JAZZ: 27.77 )
Ranked among companies with meaningful POCF only.
JAZZ' s 10-Year POCF Range
Min: 9.6  Med: 16.80 Max: 54.63
Current: 27.77
9.6
54.63
EV-to-EBIT 31.19
JAZZ's EV-to-EBIT is ranked higher than
52% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. JAZZ: 31.19 )
Ranked among companies with meaningful EV-to-EBIT only.
JAZZ' s 10-Year EV-to-EBIT Range
Min: -8.5  Med: 16.30 Max: 74.1
Current: 31.19
-8.5
74.1
PEG 1.13
JAZZ's PEG is ranked higher than
79% of the 73 Companies
in the Global Biotechnology industry.

( Industry Median: 2.63 vs. JAZZ: 1.13 )
Ranked among companies with meaningful PEG only.
JAZZ' s 10-Year PEG Range
Min: 1.3  Med: 6.25 Max: 8.62
Current: 1.13
1.3
8.62
Shiller P/E 77.92
JAZZ's Shiller P/E is ranked lower than
66% of the 109 Companies
in the Global Biotechnology industry.

( Industry Median: 49.43 vs. JAZZ: 77.92 )
Ranked among companies with meaningful Shiller P/E only.
JAZZ' s 10-Year Shiller P/E Range
Min: 71.25  Med: 114.01 Max: 11692
Current: 77.92
71.25
11692
Current Ratio 5.00
JAZZ's Current Ratio is ranked higher than
54% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. JAZZ: 5.00 )
Ranked among companies with meaningful Current Ratio only.
JAZZ' s 10-Year Current Ratio Range
Min: 0.2  Med: 2.17 Max: 5.1
Current: 5
0.2
5.1
Quick Ratio 4.86
JAZZ's Quick Ratio is ranked higher than
55% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. JAZZ: 4.86 )
Ranked among companies with meaningful Quick Ratio only.
JAZZ' s 10-Year Quick Ratio Range
Min: 0.17  Med: 2.02 Max: 4.99
Current: 4.86
0.17
4.99
Days Inventory 107.11
JAZZ's Days Inventory is ranked higher than
55% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. JAZZ: 107.11 )
Ranked among companies with meaningful Days Inventory only.
JAZZ' s 10-Year Days Inventory Range
Min: 70.82  Med: 110.71 Max: 164.69
Current: 107.11
70.82
164.69
Days Sales Outstanding 56.05
JAZZ's Days Sales Outstanding is ranked higher than
55% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. JAZZ: 56.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
JAZZ' s 10-Year Days Sales Outstanding Range
Min: 30.12  Med: 46.23 Max: 61.23
Current: 56.05
30.12
61.23

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 3.46
JAZZ's Price/Projected FCF is ranked higher than
63% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. JAZZ: 3.46 )
Ranked among companies with meaningful Price/Projected FCF only.
JAZZ' s 10-Year Price/Projected FCF Range
Min: 2.23  Med: 3.58 Max: 59.43
Current: 3.46
2.23
59.43
Price/Median PS Value 1.78
JAZZ's Price/Median PS Value is ranked lower than
70% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. JAZZ: 1.78 )
Ranked among companies with meaningful Price/Median PS Value only.
JAZZ' s 10-Year Price/Median PS Value Range
Min: 0.06  Med: 0.97 Max: 1.68
Current: 1.78
0.06
1.68
Price/Peter Lynch Fair Value 2.20
JAZZ's Price/Peter Lynch Fair Value is ranked higher than
51% of the 49 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. JAZZ: 2.20 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
JAZZ' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.04  Med: 2.03 Max: 14.94
Current: 2.2
1.04
14.94
Earnings Yield (Greenblatt) (%) 3.20
JAZZ's Earnings Yield (Greenblatt) (%) is ranked higher than
87% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. JAZZ: 3.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
JAZZ' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.3  Med: 5.50 Max: 10.7
Current: 3.2
1.3
10.7
Forward Rate of Return (Yacktman) (%) 40.32
JAZZ's Forward Rate of Return (Yacktman) (%) is ranked higher than
89% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 14.22 vs. JAZZ: 40.32 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
JAZZ' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -43.1  Med: 0.40 Max: 49.5
Current: 40.32
-43.1
49.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:J7Z.Germany,
Jazz Pharmaceuticals PLC was originally incorporated in California in March 2003 and was reincorporated in Delaware in January 2004. The Company was originally formed as a private limited liability company in March 2005 under the name Azur Pharma Limited, and was subsequently re-registered as a public limited company under the name Azur Pharma Public Limited Company in October 2011. On January 18, 2012, the business of Jazz Pharmaceuticals, Inc. and Azur Pharma were combined in the Azur Merger in connection with which Azur Pharma was re-named Jazz Pharmaceuticals plc. It is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. Its products includes Xyrem, Erwinaze, Prialt. Its commercial activities in the United States are dedicated to its marketed products Xyrem, Erwinaze, Prialt, FazaClo HD, FazaClo LD and Versacloz, as well as providing support for sales of certain of its other products. They have approximately 180 trained, experienced sales professionals who detail its marketed products to physicians in specialties appropriate for each marketed product in the United States. In Europe, they promote Erwinase to hematology and oncology specialists. The Company's commercial activities include marketing and related services and commercial support services. The Company also employ third party vendors, such as advertising agencies, market research firms and suppliers of marketing and other sales support related services, to assist with its commercial activities. Some of these competitors include Endo Health Solutions Inc., Forest Laboratories, Inc., Shire Pharmaceuticals, Inc., Teva and Valeant. Other than the manufacturing plant in Italy where they produce some active pharmaceutical ingredients, including the defibrotide drug substance, discussed in more detail below, the company do not have its own manufacturing capability for its products or product candidates, or their active pharmaceutical ingredients, or the capability to package its products. The research, testing, manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion, sale, distribution, recordkeeping, importing and exporting of pharmaceutical products are subject to extensive regulation by the FDA, the European Commission and other regulatory authorities, and regulations differ from country to country. In the United States, the FDA, under the Federal Food, Drug and Cosmetic Act, or FDCA, and its implementing regulations, regulates the review, approval, manufacturing and marketing of pharmaceutical products.
» More Articles for JAZZ

Headlines

Articles On GuruFocus.com
luca May 30 2015 
Weekly Insider Sells Highlight: MHK, JAZZ, BMY, ZAYO Mar 23 2015 
Pharmaceutical Giant Merck Buys Cubist Pharma Dec 09 2014 
Growth Momentum Should Continue For This Pharmaceutical Company Nov 15 2014 
Jazz Pharmaceuticals: Growth Trajectory Can Continue In Future Sep 03 2014 
Weekly CFO Sells Highlight: Google Inc, Jazz Pharmaceuticals PLC, Jack in the Box Inc. Jun 30 2014 
Weekly Insider Sells Highlight: JAZZ, HD, ESRX, SCI Mar 11 2014 
Weekly CFO Sells Highlight: Jazz Pharmaceuticals PLC, Carnival PLC, Juniper Networks Inc., Home Depo Mar 10 2014 
comment on JAZZ Mar 21 2013 
optimized portfolio Jul 26 2011 

More From Other Websites
Jazz Pharmaceuticals to Report 2015 Second Quarter Financial Results on August 5, 2015 Jul 22 2015
Jazz Pharmaceuticals to Report 2015 Second Quarter Financial Results on August 5, 2015 Jul 22 2015
Barclays Expects M&A In Specialty Pharma To Continue, Likes Valeant And Jazz Jul 09 2015
Rate Hikes Won't Kill Pharma M&A Boom…and These Stocks Could Be Next Jul 08 2015
Are Patent Challenges Paying Off For Kyle Bass? Jul 06 2015
Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8 Jul 01 2015
Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8 Jul 01 2015
Why Jazz Pharmaceuticals Is Winning Jun 29 2015
Jazz Pharma Still Loved At UBS, Firm Hikes Price Target To $210 Jun 29 2015
Jazz Financing I Ltd. -- Moody's assigns Ba2 to Jazz's new senior secured bank facilities; stable... Jun 19 2015
JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination... Jun 18 2015
Should Active Managers Blame the Benchmark? Jun 15 2015
Jazz Pharmaceuticals' Sleep Disorder Drug Enters Phase III - Analyst Blog Jun 09 2015
Aytu BioScience Acquires Commercial-Stage Prostate Cancer Biologic Jun 09 2015
Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program... Jun 08 2015
Jazz Pharmaceuticals to Present Abstracts from Ongoing Evaluations of Xyrem® (sodium oxybate) at... Jun 04 2015
Jazz Pharmaceuticals to Present Abstracts from Ongoing Evaluations of Xyrem® (sodium oxybate) at... Jun 04 2015
Jazz Pharmaceuticals Announces Participation in Two Investor Conferences May 15 2015
Jazz Pharmaceuticals Announces Participation in Two Investor Conferences May 15 2015
JAZZ PHARMACEUTICALS PLC Financials May 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK